What happened
ClinicalTrials.gov registry update for Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
SourceClinicalTrials.govclinical updateBiotech
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
Clinical/translation signal: Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
Factual summary
Why it matters
Clinical trial registry updates are translation signals, not commercialization claims by themselves.
SourceClinicalTrials.govLimitations
ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.
SourceClinicalTrials.govLinked output
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worseclinical trialPeople
No reviewed person relationship is attached to this event.
Organizations
Topics
No reviewed topic relationship is attached to this event.
Problems
No reviewed problem relationship is attached to this event.
Relationship evidence
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (NCT07437963)
Timeline
- clinical updateTesting the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse